Key result
DOACs linked to ~37% less major bleeding vs warfarin in elderly non-valvular AF patients.
Why the study?
Major bleeding remains a key concern with oral anticoagulation in older patients with NVAF.
Do DOACs reduce major bleeding compared to warfarin in elderly patients with non-valvular atrial fibrillation?
Population
886 elderly NVAF patients aged ≥65 years at a tertiary hospital
Comparison
DOACs vs warfarin
Design
Single-center retrospective cohort study
Authors
Loading...
Supports lower major bleeding with DOACs vs warfarin in elderly nonvalvular AF; hypothesis-generating, requires RCT confirmation before practice change.
Cohort (n=886)
No
Do DOACs reduce major bleeding compared to warfarin in elderly patients with non-valvular atrial fibrillation?
Absolute Event Rate: 6.6% vs 10.5%
In elderly patients with non-valvular atrial fibrillation, DOACs are associated with a lower prevalence of major bleeding compared to warfarin.
Kwan et al. (2025) conducted a cohort in Non-valvular atrial fibrillation (NVAF) (n=886). Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Major bleeding. Direct oral anticoagulants were associated with fewer major bleeding events compared to warfarin in elderly patients with non-valvular atrial fibrillation (6.6% vs 10.5%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: